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ESBLs, Forever?
This publication represents the proceedings of the ESCMID Conference on Extended-spectrum Beta-
lactamases and was published without commercial support. In the publication, some declarations
concerning conﬂict of interest were not included. All declarations from all authors appear below.
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The spread of CTX-M-type extended-spectrum b-lactamases
G. M. Rossolini, M. M. D’Andrea and C. Mugnaioli
GMR, MMD and CM afﬁrm that there are no conﬂicts of interest concerning the ideas expressed in this
paper. All authors acknowledge research grants from the European Commision, the Italian Ministry of
Research and University, and Wyeth Pharmaceuticals.
Minor extended-spectrum b-lactamases
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IRT and CMT b-lactamases and inhibitor resistance
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Genetic support of extended-spectrum b-lactamases
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Extended-spectrum b-lactamases and the permeability barrier
L. Martı´nez-Martı´nez
LM-M has served as a consultant for Wyeth, has been a speaker for Chiron, Wyeth and GSK, has
received research support from Chiron, Wyeth, GSK, MSD and Pﬁzer, and declares that he has no
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interest concerning the views expressed.
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